Fam-trastuzumab deruxtecan-nxki | New Drug Approvals
Antibody drug conjugate: the “biological missile” for targeted cancer therapy | Signal Transduction and Targeted Therapy
Antitumor immunity caused by combination of DS-8201a and anti-CTLA-4... | Download Scientific Diagram
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study - The Lancet Oncology
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape - ESMO Open
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer | NEJM
DESTINY-Breast01 - Capsule Summary Slidesets - Breast Cancer - 2019 SABCS - Oncology - Clinical Care Options
ds8201 - Twitter Search / Twitter
Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond | npj Breast Cancer
NCT02564900 (Clinical Trials/ DS-8201a) » ADC Review
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond | SpringerLink
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985) - ScienceDirect
Clinical Trials for Metastatic HER2-positive Breast Cancer
![iPoster : [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: a phase 3, randomized trial (](https://assets.posterview.com/SABCS/2019/1/Jpg/f/OT1-07-01.jpg "iPoster : [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: a phase 3, randomized trial (")
iPoster : [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: a phase 3, randomized trial (
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer | British Journal of Cancer
Targeted therapeutic options and future perspectives for HER2-positive breast cancer | Signal Transduction and Targeted Therapy
Enhertu ® (fam-trastuzumab deruxtecan-nxki or DS-8201a) formula, ADC... | Download Scientific Diagram
ADC Drug DS-8201 Shows Strong Efficacy in Patients with Low HER2 Breast Cancer Expression – Creative Biolabs ADC Blog
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study - The Lancet ...
Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors - Yin - 2021 - Clinical Pharmacology & Therapeutics - Wiley Online Library
NCT03248492 (Clinical Trial/ DS-8201a) » ADC Review
Structures of antibody–drug conjugates (ADCs) and released payloads.... | Download Scientific Diagram
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985) - ScienceDirect
